How Sapropterin Reduces PKU Symptoms
Sapropterin dihydrochloride (Kuvan) is a synthetic form of tetrahydrobiopterin (BH4), a cofactor for phenylalanine hydroxylase (PAH). In phenylalanine hydroxylase (PKH) deficiency, PAH cannot convert phenylalanine (Phe) to tyrosine, causing toxic Phe buildup in blood and brain. Sapropterin restores partial PAH function in responsive patients (about 20-50%), lowering blood Phe levels and easing dietary restrictions.[1]
Patients take it orally (10-20 mg/kg/day), often with a low-Phe diet. Responders see Phe drop by at least 30% within 4 weeks, improving neurotransmitter synthesis (dopamine, serotonin) and reducing neurocognitive risks like intellectual disability.[2]
Who Responds and How Quickly?
Response varies by PKU mutation—missense mutations in PAH gene predict better outcomes. A trial in 90 children showed 56% responders with Phe reductions up to 60%.[3] Adults respond less consistently (20-30%). Effects start in days but require ongoing use; stopping reverses benefits within weeks.
Impact on Long-Term Symptom Control
By normalizing Phe (target <360 μmol/L), sapropterin cuts risks of cognitive impairment, ADHD, anxiety, and seizures tied to high Phe. Studies link it to better executive function and IQ stability versus diet alone. It does not cure PKU—nonresponders rely on strict diet/glycomacropeptide.[4]
Common Side Effects and Risks
Most tolerate it well; side effects include headache (12%), runny nose (9%), and abdominal pain (8%). Rare risks: pharyngitis or hyperactivity. Monitor Phe levels monthly; not for severe PAH-null mutations.[5]
Alternatives if Sapropterin Fails
| Treatment | How It Works | Phe Reduction | Best For |
|-----------|--------------|---------------|---------|
| Low-Phe diet | Restricts protein intake | Variable (diet-dependent) | All patients |
| Pegvaliase (Palynziq) | Enzyme injection breaks down Phe | 50-80% | Adults unresponsive to sapropterin |
| Large neutral amino acids (LNAA) | Compete with Phe brain uptake | 20-40% | Dietary adjunct |
No head-to-head trials, but pegvaliase suits injection-tolerant adults.[6]
Cost and Access Factors
Annual U.S. cost exceeds $300,000 without insurance; patient assistance covers most. FDA-approved 2007 for 4+ years old; EU similar. Patent expired 2020, but no generics yet.[7]
[1]: FDA Label: Kuvan
[2]: NEJM: Sapropterin in PKU
[3]: Lancet: Pediatric Trial
[4]: Mol Genet Metab: Neurocognitive Effects
[5]: Kuvan Prescribing Info
[6]: BioMarin: Palynziq Data
[7]: DrugPatentWatch: Sapropterin